Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial.

Schmid P, McArthur HL, Cortés J, Xu B, Cardoso F, Casalnuovo M, Demirci U, Freitas-Junior R, Ghosh J, Hegg R, Iwata H, Karnaukhov I, Chuken YL, Nechaeva M, Robson ME, Villalobos-Valencia R, Yamashita T, Zurawski B, de Bruin EC, Grinsted L, D'Cruz C, Foxley A, Park YH

Open source

DOI: 10.1016/j.annonc.2025.12.012
Published: 2026 May
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2025.12.012,
  title = {Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial.},
  author = {Schmid P and McArthur HL and Cortés J and Xu B and Cardoso F and Casalnuovo M and Demirci U and Freitas-Junior R and Ghosh J and Hegg R and Iwata H and Karnaukhov I and Chuken YL and Nechaeva M and Robson ME and Villalobos-Valencia R and Yamashita T and Zurawski B and de Bruin EC and Grinsted L and D'Cruz C and Foxley A and Park YH},
  year = {2026},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2025.12.012},
  url = {https://doi.org/10.1016/j.annonc.2025.12.012}
}

RIS

TY  - JOUR
TI  - Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial.
AU  - Schmid P
AU  - McArthur HL
AU  - Cortés J
AU  - Xu B
AU  - Cardoso F
AU  - Casalnuovo M
AU  - Demirci U
AU  - Freitas-Junior R
AU  - Ghosh J
AU  - Hegg R
AU  - Iwata H
AU  - Karnaukhov I
AU  - Chuken YL
AU  - Nechaeva M
AU  - Robson ME
AU  - Villalobos-Valencia R
AU  - Yamashita T
AU  - Zurawski B
AU  - de Bruin EC
AU  - Grinsted L
AU  - D'Cruz C
AU  - Foxley A
AU  - Park YH
PY  - 2026
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2025.12.012
UR  - https://doi.org/10.1016/j.annonc.2025.12.012
ER  -

APA

P, S., HL, M., J, C., B, X., F, C., M, C., U, D., R, F., J, G., R, H., H, I., I, K., YL, C., M, N., ME, R., R, V., T, Y., B, Z., EC, D. B., L, G., C, D., A, F., & YH, P. (2026). Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2025.12.012

Source records

pubmed · retrieved 2026-09-26T03:01:54.085Z